Cargando…
Remdesivir cost effective for severe COVID-19 in China
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085793/ https://www.ncbi.nlm.nih.gov/pubmed/33948076 http://dx.doi.org/10.1007/s40274-021-7666-3 |
Ejemplares similares
-
Effects on LOS may not justify cost of remdesivir for severe COVID-19
Publicado: (2021) -
Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
Publicado: (2021) -
Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany
Publicado: (2021) -
Remdesivir appears to save costs in COVID-19 patients on low-flow oxygen therapy in Turkey
Publicado: (2021) -
Benefit-risk assessment for remdesivir in COVID-19
Publicado: (2020)